AgingResearch.NewsJoin free

HanchorBio

CompanyTaiwan

HanchorBio develops one asset, in phase 1 (HCB303 in advanced solid tumor). Mostly protein or enzyme acting on CD47, CD274 and TIGIT; based in Taiwan.

1
Asset
Furthest stage
Phase 1
0
Trials
0
Signals

Pipeline

1

  • HCB303

    Trispecific immunotherapy targeting PD-L1 and CD47 while intercepting TIGIT ligands

    Phase 1, Protein or enzyme, CD47, CD274, advanced solid tumor

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms3
  • Similar companies6

Intelligence